Now that the U.S. government has negotiated prices for some Medicare program drugs effective in 2026, Wall Street analysts are betting on a 2027 list that will include Ozempic.
The study in JAMA Network Open is the first to mine WHO's global database of suspected drug side effects for reports of suicidal thinking in patients who have taken the drugs.
A recent court defeat for CVS Health Corp. is shining a light on how healthcare corporations wield their financial might over doctors and pharmacies in ways that can put profits over patient care.